Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Stage I Cancer of the Cervix
Terminated
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which regimen of radiation therapy combined with chemotherapy, with or without surgery, is more effective in treating early cancer of the cervix. PURPOSE: Randomized phase III trial to compare the effectiveness of surgery followed by different regimens of radiation therapy and chemotherapy wit... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/10/2013
Locations: Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland
Conditions: Cervical Cancer
Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer
Terminated
RATIONALE: Vaccines made from tumor tissue may make the body build an immune response and kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy in treating patients who have stage III or stage IV ovarian epithelial cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/10/2013
Locations: Radiation Oncology Branch, Bethesda, Maryland
Conditions: Ovarian Cancer
Combination Chemotherapy Plus Sargramostim in Treating Patients With Cancer of the Uterus
Terminated
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus sargramostim in treating patients who have advanced, persistent, or recurrent can... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/10/2013
Locations: Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland
Conditions: Sarcoma
Dimesna in Treating Patients With Solid Tumors Who Are Undergoing Treatment With Cisplatin and Paclitaxel
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs such as dimesna may protect normal cells from the side effects of chemotherapy. PURPOSE: This phase I trial is studying the side effects and best dose of dimesna in treating patients with solid tumors who are receiving cisplatin and paclitaxel.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2013
Locations: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
Conditions: Head and Neck Cancer, Lung Cancer, Neurotoxicity, Ovarian Cancer
Tirapazamine Plus Cisplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining tirapazamine with cisplatin in treating patients who have recurrent ovarian epithelial or primary peritoneal cancer.
Gender:
FEMALE
Ages:
All
Trial Updated:
01/07/2012
Locations: Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland +1 locations
Conditions: Ovarian Cancer, Primary Peritoneal Cavity Cancer
Bortezomib, Cetuximab, and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage IV Head and Neck Cancer
Completed
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Radiation therapy uses high energy x- rays to kill tumor cells. Bortezomib and cetuximab may make tumor cells more sensitive to radiation therapy. Drugs used i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/29/2011
Locations: Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland
Conditions: Head and Neck Cancer
TLK286 (Telcyta) in Combination With Cisplatin for Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
Completed
The purpose of this trial is to study the efficacy and safety of the combination of TLK286 with cisplatin as first-line therapy for patients with locally advanced or metastatic non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2011
Locations: Univ. of MD, Greenbaum Cancer Center, Baltimore, Maryland
Conditions: Non-small Cell Lung Cancer
Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer
Unknown
RATIONALE: Imaging procedures, such as fludeoxyglucose F18 positron emission tomography (\^18FDG-PET), may improve the ability to detect disease progression and help doctors predict a patient's response to treatment and plan more effective treatment. PURPOSE: This phase II trial is studying how well \^18FDG-PET imaging works in detecting disease progression and determining response to treatment in patients who are undergoing chemoradiotherapy for locally advanced non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/26/2011
Locations: Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland
Conditions: Lung Cancer
Concomitant Radiation and Cisplatin With and Without Tirapazamine in Treatment of Advanced Head and Neck Cancer
Completed
The trial will compare the efficacy and safety of concomitant chemoradiation with tirapazamine, cisplatin and radiation versus cisplatin and radiation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/12/2010
Locations: Johns Hopkins Hospital, Baltimore, Maryland
Conditions: Head and Neck Neoplasms
Gemcitabine or Gemcitabine Plus Docetaxel After Cisplatin, Etoposide and Radiation in Non Small Cell Lung Cancer (NSCLC)
Completed
To assess the 2 year survival of patients with Stage III unresectable non-small cell lung cancer receiving consolidation gemcitabine or gemcitabine plus docetaxel following concurrent chemotherapy and radiation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/04/2010
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal ph, Baltimore, Maryland
Conditions: Non-small Cell Lung Cancer
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
Unknown
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase I trial to study the effect of combination chemotherapy on the body when treating patients who have relapsed or refractory aggressive non-Hodgkin's lymphoma.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
07/04/2009
Locations: Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland
Conditions: Lymphoma
Phase II Trial of Neo-Adjuvant Pemetrexed Plus Cisplatin Followed by Surgery and Radiation for Pleural Mesothelioma
Completed
This study aims to determine how successful the chemotherapy regimen of Pemetrexed plus cisplatin before surgery is at killing all the tumor so that none is left at the time of surgery. Following surgery, all eligible patients will receive radiation to the chest. How patients respond, whether the cancer returns and if so, where, will also be monitored.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/01/2009
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Baltimore, Maryland
Conditions: Pleural Neoplasms